Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.
The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.
The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself – can also take out its increasingly commonly antibiotic resistant strains.
The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.
Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.
About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.
It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.
Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.
But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.
The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.
Professor Lydia Tabernero is the project leader. She said: “The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.
“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.
“And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.
“But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”
Mycobacterium Tuberculosis secretes molecules called Virulence Factors – the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.
The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way
Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans – so our compound which blocks it is not toxic to the human cells.
“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.
“TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.
”The next stage of our research is to optimise further the chemical compound, but we hope clinical trials are up to four years away.”
Learn more: Scientists develop new drug treatment for TB
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- India turned crisis into opportunity by augmenting Tuberculosis elimination activities, says Centreon May 19, 2022 at 11:18 am
Lauding the country healthcare sector Union Minister for Health and Family Welfare Mansukh Mandaviya on Thursday said India turned a crisis into an opportuni ...
- India turned crisis into opportunity by augmenting Tuberculosis elimination activities, says Mansukh Mandaviyaon May 19, 2022 at 9:24 am
Mandaviya reiterated India's commitment to end TB and urged everyone to co-operate and collaborate at every level to achieve the 'end TB' goals ...
- 'Made in India' skin test for tuberculosis to be introduced soon: Mandaviyaon May 19, 2022 at 7:49 am
The union health minister reiterated India's commitment to end TB, and urged everyone to cooperate and collaborate at every level to achieve the ''End TB'' goals.
- Delayed Adaptive Immune Response to Tuberculosis Points to Vaccination Strategieson May 19, 2022 at 5:00 am
Researchers suggest vaccination strategies against TB should be adjusted to prime T cell responses and kick them into gear at the early stages of infection.
- Tuberculosis Testing Market Size, Company Revenue Share, Key Drivers & Trend Analysis, 20222028on May 18, 2022 at 2:56 am
Reports And Data The global tuberculosis testing market size was significantly robust in 2020 and is expected to register a steady revenue ...
- The state of tuberculosis in South Africa: what does the first national tuberculosis prevalence survey teach us?on May 17, 2022 at 3:38 pm
South Africa is among WHO's list of 30 high-burden tuberculosis countries and has one of the highest incidence rates of notified tuberculosis in the world.1 In The Lancet Infectious Diseases, Sizulu ...
- Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional surveyon May 17, 2022 at 3:33 pm
Tuberculosis remains an important clinical and public health issue in South Africa, which has one of the highest tuberculosis burdens in the world. We aimed to estimate the burden of bacteriologically ...
- Tuberculosis Is the Oldest Pandemic, and Poverty Makes It Continueon May 17, 2022 at 9:25 am
She was diagnosed with tuberculosis, a disease at least 9,000 years old that has likely killed more people than any other plague—as many as one billion in the past 200 years. Although the illness may ...
- Dynamics of adaptive immunity in tuberculosis uncoveredon May 17, 2022 at 8:00 am
Unlike other infectious diseases that affect the lungs, the immune response to fight tuberculosis (TB) infections develops at least twice as slowly. Until recently, the dynamic interplay between ...
via Bing News